TITLE

Hepatitis A, B and C viral co-infections among HIV-infected adults presenting for care and treatment at Muhimbili National Hospital in Dar es Salaam, Tanzania

AUTHOR(S)
Nagu, Tumaini J.; Bakari, Muhammad; Matee, Mecky
PUB. DATE
January 2008
SOURCE
BMC Public Health;2008, Vol. 8 Issue 1, p416
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Tanzania is currently scaling-up access to anti-retro viral therapy (ART) to reach as many eligible persons as possible. Hepatitis viral co-infections are known to influence progression, management as well as outcome of HIV infection. However, information is scarce regarding the prevalence and predictors of viral hepatitis co-infection among HIV-infected individuals presenting at the HIV care and treatment clinics in the country. Methods: A cross-sectional study conducted between April and September 2006 enrolled 260 HIV-1 infected, HAART naïve patients aged ≥18 years presenting at the HIV care and treatment clinic (CTC) of the Muhimbili National Hospital (MNH). The evaluation included clinical assessment and determination of CD4+ T-lymphocyte count, serum transaminases and serology for Hepatitis A, B and C markers by ELISA. Results: The prevalence of anti HAV IgM, HBsAg, anti-HBc IgM and anti-HCV IgG antibodies were 3.1%, 17.3%, 2.3% and 18.1%, respectively. Dual co-infection with HBV and HCV occurred in 10 individuals (3.9%), while that of HAV and HBV was detected in two subjects (0.8%). None of the patients had all the three hepatitis viruses. Most patients (81.1%) with hepatitis co-infection neither had specific clinical features nor raised serum transaminases. History of blood transfusion and jaundice were independent predictors for HBsAg and anti-HBc IgM positivity, respectively. Conclusion: There is high prevalence of markers for hepatitis B and C infections among HIV infected patients seeking care and treatment at MNH. Clinical features and a raise in serum alanine aminotransferase were of limited predictive values for the viral co-infections. Efforts to scale up HAART should also address co-infections with Hepatitis B and C viruses.
ACCESSION #
51491782

 

Related Articles

  • Evaluation and Treatment of the HIV/HCV Coinfected Patient: A Case History and Discussion. McGovern, Barbara // AIDS Patient Care & STDs;Jul2002, Vol. 16 Issue 7, p319 

    Declining rates of morbidity and mortality related to opportunistic infections in the era of highly active antiretroviral therapy (HAART) have led to a new focus on hepatitis C (HCV). Several studies suggest that the natural history of HCV is accelerated in patients with HIV infection. Recent...

  • Transmission Fitness of Drug-Resistant Human Immunodeficiency Virus and the Prevalence of Resistance in the Antiretroviral-Treated Population. Brown, Andrew J. Leigh; Frost, Simon D.W.; Mathews, W. Christopher; Dawson, Keith; Hellmann, Nicholas S.; Daar, Eric S.; Richman, Douglas D.; Little, Susan J. // Journal of Infectious Diseases;2/15/2003, Vol. 187 Issue 4, p683 

    Although the prevalence of drug-resistant strains in primary human immunodeficiency virus (HIV) infection in North America has recently increased, their transmission fitness remains unknown. The present study estimated the frequency of transmission of drug-resistant HIV from patients receiving...

  • The Consistency of Adherence to Antiretroviral Therapy Predicts Biologic Outcomes for Human Immunodeficiency Virus-Infected Persons in Clinical Trials. Mannheimer, Sharon; Friedland, Gerald; Matts, John; Child, Carroll; Chesney, Margaret // Clinical Infectious Diseases;4/15/2002, Vol. 34 Issue 8, p1115 

    We prospectively studied long-term antiretroviral adherence patterns and their impact on biologic outcomes for human immunodeficiency virus (HIV)-infected participants in 2 randomized, multicenter clinical trials. For the period from baseline to month 12 of the study, participants who reported...

  • Intensification and Stimulation Therapy for Human Immunodeficiency Virus Type 1 Reservoirs in Infected Persons Receiving Virally Suppressive Highly Active Antiretroviral Therapy. Kulkosky, Joseph; Nunnari, Giuseppe; Otero, Miguel; Calarota, Sandra; Dornadula, Geetha; Hui Zhang; Malin, Anne; Sullivan, Julie; Yan Xu; DeSimone, Joseph; Babinchak, Timothy; Stern, John; Cavert, Winston; Haase, Ashley; Pomerantz, Roger J. // Journal of Infectious Diseases;11/15/2002, Vol. 186 Issue 10, p1403 

    Highly active antiretroviral therapy (HAART) has led to significant changes in mortality and morbidity in the human immunodeficiency virus type 1 (HIV-1) epidemic. Nevertheless, because of molecular mechanisms of viral persistence, HAART does not eradicate HIV-1. Didanosine and hydroxyurea were...

  • A Multi-sectorial Committee in Directing HIV/AIDS-Specific Interventions in the Occupational... Morris, Chester N.; Wilkinson, David; Stein, Zena; Cheevers, E.J. // AIDS Patient Care & STDs;Mar2001, Vol. 15 Issue 3, p153 

    Presents a descriptive analysis of a mechanism to coordinate and implement HIV prevention and care in the occupational setting. Composition of the multidisciplinary committee described; Initiation of the committee to coordinate a combined prevention-care initiative; Issues cited as important in...

  • Therapy Adherence and Highly Active Antiretroviral Therapy: Comparison of Three Sources of Information. Vincke, John; Bolton, Ralph // AIDS Patient Care & STDs;Oct2002, Vol. 16 Issue 10, p487 

    With the advent of the highly active antiretroviral therapy (HAART), adherence became one of the key issues within the behavioral management of the treatment of human immunodeficiency virus (HIV) infection. One of the central limitations in studying adherence to HAART is that usually one has to...

  • Clinical Indicators of Immune Restoration following Highly Active Antiretroviral Therapy. Cooney, Elizabeth L. // Clinical Infectious Diseases;1/15/2002, Vol. 34 Issue 2, p224 

    The course of human immunodeficiency virus (HIV) disease is characterized by a progressive decline in immune function. The advent of highly active antiretroviral therapy (HAART) has allowed patients to experience a significant degree of immune restoration when compared with the era before the...

  • Reconsidering Antiretroviral Therapy in HIV: Lessons from San Francisco. Laurence, Jeffrey // AIDS Patient Care & STDs;Apr2000, Vol. 14 Issue 4, p175 

    Editorial. Discusses the findings of studies presented at the 7th Conference on Retroviruses and Opportunistic Infections held in San Francisco, California, concerning the impact of structured treatment interruption on HIV-positive persons who had been receiving antiretroviral therapy. Absence...

  • The Impact of Early Initiation of Highly Active Antiretroviral Therapy... Spiegel, Hans M.L.; Chandwani, Rohit; Sheehy, Megan E.; Dobroszycki, Joanna; Fennelly, Glenn; Wiznia, Andrew; Radding, Jayme; Rigaud, Mona; Pollack, Henry; Borkowsky, William; Rosenberg, Michael; Nixon, Douglas F. // Journal of Infectious Diseases;7/1/2000, Vol. 182 Issue 1, p88 

    Examines the effect of early highly active antiretroviral therapy (HAART) on HIV type 1 (HIV-1) infection-specific CD8 T cell responses in children. Measurement of plasma HIV-1 RNA load; Isolation of peripheral blood mononuclear cells; Recombinant vaccinia vectors; Comparison of total...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics